• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Pernix Therapeutics Holdings, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It focuses on therapeutics for diseases on central nervous system, neurology, pain, and psychiatry. Its products include treatment of migraine pain and inflammation, insomnia, and depressive disorder. The firm distributes its products under the following brands: Treximet, Silenor, Zohydro ER with BeadTek, and Khedezla. The company was founded on March 9, 2010 and is headquartered in The Woodlands, TX.
Market Cap | 420.79 Thousand | Shares Outstanding | 14.51 Million | Avg 30-day Volume | 25.828 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.89 |
Price to Revenue | 0.1002 | Debt to Equity | -0.7537 | EBITDA | -3.828 Million |
Price to Book Value | 0.0 | Operating Margin | -38.1273 | Enterprise Value | 150.657 Million |
Current Ratio | 1.082 | EPS Growth | 0.576 | Quick Ratio | 0.815 |
1 Yr BETA | 0.0982 | 52-week High/Low | 0.0 / | Profit Margin | -67.125 |
Operating Cash Flow Growth | -681.7603 | Altman Z-Score | -2.4863 | Free Cash Flow to Firm | -23.277 Million |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
PINA KENNETH SVP, GC,COMPLIANCE OFF & SEC |
|
14,726 | 2019-01-05 | 0 |
SEDOR JOHN A CHAIRMAN OF BOARD AND CEO |
|
133,140 | 2018-08-08 | 0 |
WHALEY GLENN VP OF FIN, PAO & CONTROLLER |
|
3,616 | 2018-08-08 | 0 |
SMITH ANGUS W. SVP, CBO & PRINCIPAL FIN OFF |
|
8,018 | 2018-08-08 | 0 |
|
0 | 2018-05-22 | 0 | |
|
0 | 2018-05-22 | 0 | |
|
0 | 2018-05-22 | 0 | |
|
0 | 2018-05-22 | 0 | |
MIAO GRAHAM G PRESIDENT AND CFO |
|
64,035 | 2017-08-08 | 0 |
GOLEMBIEWSKI MICHAEL JOSEPH VP FINANCE, CONTROLLER, CAO |
|
3,300 | 2017-08-08 | 0 |
|
2,000,000 | 2016-05-26 | 0 | |
|
0 | 2016-05-26 | 0 | |
NOVAK TERENCE CHIEF OPERATING OFFICER |
|
0 | 2016-02-25 | 0 |
DRYSDALE DOUGLAS CHIEF EXECUTIVE OFFICER |
|
0 | 2016-02-25 | 0 |
SHALABY RICK SVP COMMERCIAL OPERATIONS |
|
0 | 2016-02-25 | 0 |
PATEL SANJAY S CHIEF FINANCIAL OFFICER |
|
0 | 2016-02-25 | 0 |
SIEGEL BARRY J SENIOR VP AND GENERAL COUNSEL |
|
0 | 2016-02-25 | 0 |
CLIFFORD TRACY SIMMONS PRINCIPAL ACCOUNTING OFFICER |
|
7,506 | 2014-11-03 | 0 |
DORSEY BRIAN SVP RESEARCH |
|
87,426 | 2014-10-10 | 0 |
|
3,501,704 | 2014-05-19 | 0 | |
COLLINS COOPER C. CHIEF STRATEGIC OFFICER |
|
3,526,571 | 2014-04-01 | 0 |
PEARCE MICHAEL COOPER PRESIDENT AND CEO |
|
286,667 | 2013-05-10 | 0 |
BECKER DAVID PAUL CHIEF FINANCIAL OFFICER |
|
200,000 | 2012-12-07 | 0 |
|
45,000 | 2012-03-22 | 0 | |
HRUSHKA CHARLES S VP OF SALES AND MARKETING |
|
0 | 2012-01-20 | 0 |
|
448,550 | 2011-03-11 | 0 | |
VENTERS MICHAEL EXECUTIVE VP OF OPERATIONS |
|
0 | 2010-05-12 | 0 |
|
0 | 2010-01-03 | 0 | |
|
0 | 2010-01-03 | 0 | |
|
474,800 | 2008-05-30 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|
Holder | Issuer | Net Short Position | Position Date | Origin |
---|